Results 231 to 240 of about 18,162 (243)

Raltegravir: a new antiretroviral class for salvage therapy

Lancet, The, 2007
Omar Sued
exaly  

Raltegravir: a new choice in HIV and new chances for research

Lancet, The, 2009
Sean Emery, Alan Winston
exaly  

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

New England Journal of Medicine, 2008
Jose M Gatell, Adriano Lazzarin, Bonaventura Clotet   +2 more
exaly  

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

Lancet, The, 2014
Laura Richert, jean-michel Molina, Elizabeth C George   +2 more
exaly  

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Nature Medicine, 2010
Marta Massanella, Viktor Dahl, Maria C Puertas   +2 more
exaly  

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Lancet Infectious Diseases, The, 2011
Joseph J Eron, Jaime F Andrade-Villanueva, Linda-Gail Bekker   +2 more
exaly  

Raltegravir

Reactions Weekly, 2011
openaire   +2 more sources

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

Lancet Infectious Diseases, The, 2013
Maria Eugenia Quiros Roldan, Jose M Gatell, Pere Domingo   +2 more
exaly  

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

Pharmacological Research, 2012
Cristina Gervasoni, paola meraviglia, Giuliano Rizzardini   +2 more
exaly  

Raltegravir

Reactions Weekly
openaire   +1 more source